Literature DB >> 3753829

Continuous infusion of atracurium in children.

N Goudsouzian, J Martyn, G D Rudd, L M Liu, C G Lineberry.   

Abstract

Atracurium infusion requirements were determined in 28 children anesthetized with N2O:O2 narcotic, N2O:O2 halothane (1% inspired), and N2O:O2 enflurane (2% inspired). When the patient was recovering from a bolus dose of 0.4 mg/kg atracurium, a continuous infusion of atracurium was started and the rate was adjusted to maintain 90-99% muscle twitch depression. Patients receiving enflurane anesthesia required atracurium at an infusion rate of 4.9 +/- 0.3 micrograms X kg-1 X min-1 which was a significantly lower rate (P = 0.0001) than those anesthetized with halothane (8.3 +/- 0.4 micrograms X kg-1 X min-1) or with N2O:O2 and narcotic (9.3 +/- 0.5 micrograms X kg-1 X min-1). At the onset of neuromuscular blockade, the twitch response disappeared faster after train-of-four stimulation repeated every 10 s than after single twitch rates of stimulation at 0.1 Hz. In children, during halothane anesthesia after 0.4 mg/kg atracurium, the response of the adductor of the thumb was ablated in 2.0 +/- 0.3 min with train-of-four stimulation, and in 3.7 +/- 0.4 min with single twitch stimulation. The authors recommend the use of a nerve stimulator during continuous infusion of atracurium because of the marked interpatient differences in infusion-rate requirements.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3753829     DOI: 10.1097/00000542-198602000-00007

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  2 in total

1.  Quantifying the effect of enflurane on atracurium infusion requirements.

Authors:  M Kansanaho; K T Olkkola
Journal:  Can J Anaesth       Date:  1995-02       Impact factor: 5.063

2.  Continuous infusions of atracurium and vecuronium, compared with intermittent boluses of pancuronium: dose requirements and reversal.

Authors:  W S Beattie; D N Buckley; J B Forrest
Journal:  Can J Anaesth       Date:  1992-11       Impact factor: 5.063

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.